Ocean Biomedical, Inc.

Ocean Biomedical, Inc. (Nasdaq: OCEA) is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination with Aesther Healthcare Acquisition Corp in February 2023. The blank-check vehicle, sponsored by Aesther Healthcare Sponsor LLC, conducted its IPO in 2021 targeting the healthcare and life sciences sector. Ocean Biomedical focuses on developing novel therapeutics across oncology, fibrosis, and infectious disease indications, drawing on research partnerships with Brown University. The company filed an 8-K with the SEC on July 23, 2024, under accession number 0001493152-24-028844, continuing its post-merger public reporting obligations on Nasdaq. Investors and analysts tracking OCEA can access the full filing history, deal analytics, and post-merger data by signing up at SpacDesk.